SignalSilence® LIMK1 siRNA IProduct information
|300 µl (3 nmol)||-||Unavailable in your region|
Product Pathways - Cytoskeletal Signaling
SignalSilence® LIMK1 siRNA I #4559
|4559S||300 µl (3 nmol)||---||In Stock||---|
|4559||carrier free and custom formulation / quantity||email request|
Product is assembled upon order. Please allow up to three business days for your product to be processed.
Species predicted to react based on 100% sequence homology: Monkey.
Western blot analysis of extracts from 293T cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-), SignalSilence® LIMK1 siRNA I (+), or SignalSilence® LIMK1 siRNA II #7156 (+), using LIMK1 Antibody #3842 (upper) or β-Actin (D6A8) Rabbit mAb #8457 (lower). The LIMK1 Antibody confirms silencing of LIMK1 expression, while the β-Actin (D6A8) Rabbit mAb is used as a loading control.
SignalSilence® LIMK1 siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit LIMK1 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions For Use
CST recommends transfection with 100 nM SignalSilence® LIMK1 siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
LIM kinases (LIMK1 and LIMK2) are serine/threonine kinases that have two zinc finger motifs, known as LIM motifs, in their amino-terminal regulatory domains (1). LIM kinases are involved in actin cytoskeletal regulation downstream of Rho-family GTPases, PAKs, and ROCK (2,3). PAK1 and ROCK phosphorylate LIMK1 or LIMK2 at the conserved Thr508 or Thr505 residues in the activation loop, increasing LIMK activity (3-5). Activated LIM kinases inhibit the actin depolymerization activity of cofilin by phosphorylation at the amino-terminal Ser3 residue of cofilin (6,7).
- Okano, I. et al. (1995) J. Biol. Chem. 270, 31321-31330.
- Maekawa, M. et al. (1999) Science 285, 895-898.
- Edwards, D. C. et al. (1999) Nat. Cell Biol. 1, 253-259.
- Ohashi, K. et al. (2000) J. Biol. Chem. 275, 3577-3582.
- Sumi, T. et al. (2001) J. Biol. Chem. 276, 670-676.
- Arber, S. et al. (1998) Nature 393, 805-809.
- Yang, N. et al. (1998) Nature 393, 809-812.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
SignalSilence is a registered trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.